Pfizer & Allergan: Who’s Getting the Better Deal?
December 02, 2015 at 12:21 PM EST
Which company’s shareholders make out better from the merger between Pfizer (PFE) and Allergan (AGN)? According to Leerink analyst Seamus Fernandez, a sum-of-the-parts analysis of the new company created by the merger, slated to close next year, suggests a value of $37 to $38 a share. That’s consistent with Fernandez’s existing $37 price target for […]
